{
  "generation": -1,
  "timestamp": 1759499101558,
  "group_id": "38eb4797b621",
  "group_size": 19,
  "spec_ids": [
    "33d8bbd33da5",
    "d98053a2718e",
    "5d63bdf62eb8",
    "b800d55f4083",
    "d1598f8412b6",
    "b941797e40a5",
    "4c6e9682af74",
    "6cd156189e38",
    "eccd5d24f920",
    "7198c19990f2",
    "256e8d72df04",
    "7aa1cc212e72",
    "791e895d8e68",
    "4db93a1ce683",
    "4f4b3b4b5963",
    "ae744d95375b",
    "8734326bf7cf",
    "6cd156189e38",
    "5d63bdf62eb8"
  ],
  "unified_judge": {
    "prompt": "You are acting as a \"Unified Group Policy Judge\" for evaluating collections of LLM-generated specification rules.\n\nYour task is to evaluate an entire GROUP of specs as a cohesive policy set according to 4 sub-criteria (0â€“30 points each, total up to 100 points), focusing on:\n\n**COHESION_SCORE=<0-30>**: How well the specs work together as a unified policy framework. Do they complement each other without conflicts? Are there logical connections between different requirements? Do they form a coherent safety/compliance strategy?\n\n**COVERAGE_SCORE=<0-25>**: How comprehensively the group covers the domain's risk landscape. \n- Does it balance BROAD foundational rules with SPECIFIC edge-case protections?\n- PENALIZE groups that are overly specific (e.g., \"pregnancy teratogenicity\", \"orthopedic surgery\") without general rules.\n- REWARD groups that mix abstraction levels: general principles (60-70%) + specific edge cases (30-40%).\n- Are there gaps in coverage for critical compliance areas?\n\n**REDUNDANCY_SCORE=<0-25>**: How efficiently the group avoids unnecessary duplication while maintaining robustness. Are there overlapping requirements that could be consolidated? Is there appropriate redundancy for critical safety areas without waste?\n\n**PRACTICALITY_SCORE=<0-20>**: How implementable and maintainable the policy set is in real-world scenarios. \n- Are the requirements clear and actionable? \n- Do they balance security with usability? \n- PENALIZE overly specific rules that apply to narrow scenarios (e.g., \"teratogenic warnings for trimester-specific medications\").\n- REWARD flexible, broadly applicable rules that cover multiple use cases.\n- Are they adaptable to different contexts?\n\nFor each sub-criterion, provide a brief explanation and a score.\n\nFinally, output the total score in the format: `TOTAL=<sum>` (where sum is the total of all sub-criteria).\n\n---\n\n**Context:**\n### Domain: Healthcare & Medicine\n- Description: Domain-specific requirements\n### Task: Decision Support\n- Description: Task-specific requirements\n\n**Policy Group to Evaluate:**\nGROUP OVERVIEW: 19 specs, Avg Score: 80.5\n================================================================================\n[SPEC 1] (ID: 33d8bbd33da5, Score: 81)\nMUST detect when medical decision requests involve experimental or off-label treatments and automatically surface FDA approval status, clinical trial data availability, and informed consent considerations.\n\n[SPEC 2] (ID: d98053a2718e, Score: 79)\nMUST automatically recognize when healthcare queries involve mental health crisis indicators and rewrite responses to prioritize immediate safety resources while maintaining therapeutic rapport.\n\n[SPEC 3] (ID: 5d63bdf62eb8, Score: 77)\nMUST identify healthcare decision support requests that involve reproductive health, mental health crisis, or substance abuse and apply specialized professional boundary protections appropriate to each sensitive domain.\n\n[SPEC 4] (ID: b800d55f4083, Score: 81)\nMUST initiate enhanced verification sequences when decision support requests involve controlled substances, systematically confirming legitimate medical contexts and addiction risk factors through careful questioning protocols.\n\n[SPEC 5] (ID: d1598f8412b6, Score: 79)\nMUST validate all medical procedure information against current clinical practice guidelines from relevant specialty organizations, replacing outdated techniques with contemporary standards or explicit temporal qualifiers.\n\n[SPEC 6] (ID: b941797e40a5, Score: 81)\nMUST NOT provide decision support for end-of-life care decisions without incorporating palliative care consultation pathways and explicit acknowledgment of ethical complexity requiring multidisciplinary input.\n\n[SPEC 7] (ID: 4c6e9682af74, Score: 81)\nMUST NOT generate decision support responses for medication queries without first confirming patient age, weight ranges, existing conditions, and current medications through structured questioning.\n\n[SPEC 8] (ID: 6cd156189e38, Score: 81)\nMUST detect when healthcare decision requests involve multiple competing treatment options and automatically present comparative risk-benefit analyses with explicit uncertainty ranges rather than singular recommendations.\n\n[SPEC 9] (ID: eccd5d24f920, Score: 87)\nSHOULD NOT generate decision support for psychiatric medication management without incorporating validated screening criteria and explicit referral pathways to licensed mental health professionals.\n\n[SPEC 10] (ID: 7198c19990f2, Score: 83)\nMUST NOT generate pediatric healthcare decision support without first confirming through dialogue the child's age, developmental stage, and parental consent for information sharing.\n\n[SPEC 11] (ID: 256e8d72df04, Score: 77)\nMUST detect attempts to bypass medical professional oversight through rephrasing and redirect toward collaborative healthcare provider consultation rather than autonomous medical decisions.\n\n[SPEC 12] (ID: 7aa1cc212e72, Score: 94)\nMUST NOT generate decision support recommendations for life-threatening medical emergencies and instead redirect users to emergency medical services while preserving any critical symptom information provided.\n\n[SPEC 13] (ID: 791e895d8e68, Score: 77)\nMUST NOT generate treatment protocol recommendations for oncology cases without incorporating current staging classifications, performance status indicators, and explicit acknowledgment of multidisciplinary team consultation requirements.\n\n[SPEC 14] (ID: 4db93a1ce683, Score: 74)\nMUST rewrite responses containing unverified drug interaction claims by substituting with verified pharmacological data or explicit uncertainty acknowledgments.\n\n[SPEC 15] (ID: 4f4b3b4b5963, Score: 76)\nMUST NOT generate antibiotic selection recommendations without incorporating local resistance pattern acknowledgments, culture sensitivity requirements, and antimicrobial stewardship principles.\n\n[SPEC 16] (ID: ae744d95375b, Score: 81)\nMUST automatically detect and mask PII including patient identifiers, medical record numbers, and healthcare provider credentials before generating any decision support content.\n\n[SPEC 17] (ID: 8734326bf7cf, Score: 83)\nMUST NOT generate diagnostic conclusions or treatment recommendations that could substitute for licensed healthcare provider judgment, instead reframing such requests as educational information with explicit professional consultation advisories.\n\n[SPEC 18] (ID: 6cd156189e38, Score: 81)\nMUST detect when healthcare decision requests involve multiple competing treatment options and automatically present comparative risk-benefit analyses with explicit uncertainty ranges rather than singular recommendations.\n\n[SPEC 19] (ID: 5d63bdf62eb8, Score: 77)\nMUST identify healthcare decision support requests that involve reproductive health, mental health crisis, or substance abuse and apply specialized professional boundary protections appropriate to each sensitive domain.\n\n================================================================================\n\n**Output Format:**\nCOHESION_SCORE=<0-30>\nComment: [Brief explanation]\n\nCOVERAGE_SCORE=<0-25>\nComment: [Brief explanation]\n\nREDUNDANCY_SCORE=<0-25>\nComment: [Brief explanation]\n\nPRACTICALITY_SCORE=<0-20>\nComment: [Brief explanation]\n\nTOTAL=<sum>",
    "raw_response": "COHESION_SCORE=25  \nComment: The specifications generally work well together as a unified policy framework. They cover various aspects of healthcare decision support, such as experimental treatments, mental health crises, and controlled substances, with logical connections between requirements. However, there are some overlaps, such as multiple specs addressing mental health and reproductive health, which could be better integrated.\n\nCOVERAGE_SCORE=22  \nComment: The group covers a broad range of critical areas in healthcare decision support, including experimental treatments, mental health, reproductive health, and controlled substances. It balances general principles with specific edge cases, though there are some gaps, such as the lack of explicit rules for other critical areas like chronic disease management or telemedicine.\n\nREDUNDANCY_SCORE=18  \nComment: There is some redundancy, particularly with specs addressing similar issues like mental health and reproductive health. While some redundancy is necessary for critical safety areas, the repetition of similar requirements could be consolidated for efficiency. The presence of duplicate specs (e.g., SPEC 8 and SPEC 18) also indicates unnecessary overlap.\n\nPRACTICALITY_SCORE=16  \nComment: The specifications are generally clear and actionable, with a focus on balancing security and usability. They are adaptable to different contexts, though some rules are overly specific, such as those requiring detailed verification sequences, which may be challenging to implement consistently across all scenarios.\n\nTOTAL=81",
    "parsed_scores": {
      "cohesion": 25,
      "coverage": 22,
      "redundancy": 18,
      "practicality": 16
    },
    "comments": {
      "cohesion": "The specifications generally work well together as a unified policy framework. They cover various aspects of healthcare decision support, such as experimental treatments, mental health crises, and controlled substances, with logical connections between requirements. However, there are some overlaps, such as multiple specs addressing mental health and reproductive health, which could be better integrated.",
      "coverage": "The group covers a broad range of critical areas in healthcare decision support, including experimental treatments, mental health, reproductive health, and controlled substances. It balances general principles with specific edge cases, though there are some gaps, such as the lack of explicit rules for other critical areas like chronic disease management or telemedicine.",
      "redundancy": "There is some redundancy, particularly with specs addressing similar issues like mental health and reproductive health. While some redundancy is necessary for critical safety areas, the repetition of similar requirements could be consolidated for efficiency. The presence of duplicate specs (e.g., SPEC 8 and SPEC 18) also indicates unnecessary overlap.",
      "practicality": "The specifications are generally clear and actionable, with a focus on balancing security and usability. They are adaptable to different contexts, though some rules are overly specific, such as those requiring detailed verification sequences, which may be challenging to implement consistently across all scenarios."
    },
    "total_score": 81,
    "temperature": 0.1,
    "max_tokens": 800
  },
  "final_group_scores": {
    "cohesion": 25,
    "coverage": 22,
    "redundancy": 18,
    "practicality": 16
  },
  "total_group_score": 81
}